DBV Technologies vs Fate Therapeutics
DBVT and FATE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DBVT and FATE compare
DBV Technologies is the larger company, worth 19 times as much as Fate Therapeutics ($3.6B against $192M).
DBV Technologies grew revenue faster over the last twelve months (−31.6% versus −33.4% for Fate Therapeutics).
Fate Therapeutics keeps more of each dollar of sales as profit, with a net margin of −2620% compared with −5405% at DBV Technologies.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DBVT | FATE |
|---|---|---|
| Size and price | ||
| Market cap | $3.6B | $192M |
| Share price | $11.51 | $1.60 |
| Change, 1 year | −17.6% | 47.2% |
| Change, 5 years | 88.1% | −97.1% |
| Beta (5Y) | 0.58 | 2.46 |
| Employees | 125 | 161 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 943× | 40.5× (better) |
| P/B | 24.4× | 1.4× (better) |
| FCF yield | −5.3% (better) | −55.6% |
| Fair value | – | $1.16 |
| Margin of safety | – | −38.8% |
| Growth | ||
| Revenue growth (TTM) | −31.6% (better) | −33.4% |
| Revenue growth, 5Y average | −13.0% (better) | −26.7% |
| Profitability | ||
| Operating margin | −5432% | −2760% (better) |
| Net margin | −5405% | −2620% (better) |
| FCF margin | −4998% | −2249% (better) |
| Return on equity | −206% | −67.8% (better) |
| Return on invested capital | – | −1647% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 3.24 | 4.41 (better) |
| Altman Z-score | 27.93 (better) | −9.69 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 6.8% | 59.9% |
| Held by insiders | 12.1% | 25.7% |
| Insider net buying, 12 months | −$15.5M | −$336K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | – | 11.2% |
Go deeper
- DBVT stock overview
- DBVT income statement
- DBVT valuation and score
- FATE stock overview
- FATE income statement
- FATE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.